ReviewOncoTargets and therapy2014
Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives.
Review in OncoTargets and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- A novel prognostic model based on MVIRGs identifies ANGPT2 as a key target driving the malignant progression of HCC.Biological procedures online · 2026Article
- Exosome-loading miR-205: a two-pronged approach to ocular neovascularization therapy.Journal of nanobiotechnology · 2025Article
- Article
- A Nucleic Acid-Based LYTAC Plus Platform to Simultaneously Mediate Disease-Driven Protein Downregulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Titanium nanotubes modulate immunophenotyping and cytokine secretion of T cells via IL-17A: a bioinformatic analysis and experimental validation.Frontiers in immunology · 2024Article
- Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies.Medicina (Kaunas, Lithuania) · 2023Review
- Homeobox D9 drives the malignant phenotypes and enhances the Programmed death ligand-1 expression in non-small cell lung cancer cells via binding to Angiopoietin-2 promoter.World journal of surgical oncology · 2023Article
- Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.Cancer biology & medicine · 2023Review
- LncRNAs in non-small cell lung cancer: novel diagnostic and prognostic biomarkers.Frontiers in molecular biosciences · 2023Review
- Neutrophil Extracellular Traps, Angiogenesis and Cancer.Biomedicines · 2022Review
- Review
- RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?Frontiers in oncology · 2022Review
- Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma.Oncotarget · 2018Article
- Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy.International journal of molecular sciences · 2018Review
- Serum biomarker analysis in patients with recurrent spontaneous abortion.Molecular medicine reports · 2017Article
- A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy.International journal of molecular sciences · 2017Review
- From big data to diagnosis and prognosis: gene expression signatures in liver hepatocellular carcinoma.PeerJ · 2017Article
- Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis.World journal of surgical oncology · 2016Article
- A double suicide gene system driven by vascular endothelial growth factor promoter selectively kills human hepatocellular carcinoma cells.Oncology letters · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a hypervascular malignancy and is the third leading cause of death worldwide. The disease has multiple predisposing risk factors and limited treatment options. Although the precise mechanism(s) underlying HCC is unknown, several pathways have been implicated in its development. HCC is a vascular tumor and angiogenesis is believed to play an important role in its progression. Hypoxia is believed to increase the expression of vascular endothelial growth factor (VEGF) through the expression of the hypoxia-inducible factor-1α. VEGF and angiopoietin 2 (Ang2) are expressed on cancer cells, whereas angiopoietin 1 (Ang1) occurs predominantly in support cells of large blood cells as well as stromal, endothelial, and tumor cells. Ang2 is concomitantly an agonist and antagonist of angiopoietin 1 and is expressed during vascular remodeling. This prevents vascular stability and allows VEGF to stimulate endothelial cells. Ang2 is expressed along with growing blood vessels, destabilizing the vascular integrity. Inhibiting Ang2 can, on the other hand, promote vesicular stability and decrease angiogenesis. We discuss in this review angiopoietin as a therapeutic target alone or in combination with other therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.